Analyst Downgrades Gossamer Bio As Merck’s Sotatercept Might Overshadow Seralutinib’s Success
Raymond James has downgraded Gossamer Bio Inc (NASDAQ:GOSS) to Market Perform from Outperform following the publication of sotatercept’s Phase 3 data in NEJM. …
FDA’s Regulatory Delay is The Reason For Novavax, Lucira Health’s Failure: WSJ Report
Failures of Covid vaccine maker Novavax Inc (NASDAQ: NVAX) and diagnostic start-up Lucira Health Inc (NASDAQ: LHDX) show that companies often succeed or fail, owing to the whims of the government.&nb
‘Qualigen Peer-Reviewed Journal Article Out Titled “The Potent G-Quadruplex-Binding Compound QN-302 Downregulates S100p Gene Expression In Cells And In An In Vivo Model Of Pancreatic Cancer”‘
https://www.mdpi.com/1420-3049/28/6/2452
Abstract
The naphthalene diimide compound QN-302, designed to bind to G-quadruplex DNA sequences within the promoter regions of cancer-related genes, has high anti-proliferative
Caris Life Sciences Announced A Strategic Research Partnership With Incyte To Augment Precision Medicine Approaches For Incyte’s Oncology Pipeline; Deal Terms Not Disclosed
Incyte will leverage Caris' data insights and analytics capabilities to discover novel biomarkers and optimize clinical positioning strategies for its oncology programs.
For drug candidates developed under the
Dupixent Application For Treatment Of Chronic Spontaneous Urticaria In Adults And Adolescents Accepted For FDA Review
Dupixent® (dupilumab) application for treatment of chronic spontaneous urticaria (CSU) in adults and adolescents accepted for FDA review
More than 300,000 people in the
Reported Late Monday March 06, BioMarin Provides Update On FDA Review Of ROCTAVIAN Gene Therapy For Adults With Severe Hemophilia A; FDA Extends PDUFA Target Action Date To June 30, 2023
FDA Extends PDUFA Target Action Date to June 30, 2023
SAN RAFAEL, Calif., March 6, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), a global biotechnology company dedicated to transforming
Why BioMarin Shares Are Plunging Today?
Biomarin Pharmaceutical Inc (NASDAQ: BMRN) shares are falling in reaction to positive data from BridgeBio Pharma Inc's (NASDAQ: BBIO) dwarfism drug, heating the competition.